The resubmitted sBLA will include results from Study C, which evaluated biologic-naive patients with uncontrolled CSU on antihistamines.
Danziten is a twice daily, oral medication that inhibits the BCR-ABL tyrosine kinase. Nilotinib was originally approved under the brand name Tasigna; it is currently indicated for adults and pediatric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback